Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Articles
Articles
Patient-Centered Oncology Medical Home Improves Health Outcomes at Lower Costs to Patients and Payers
By
Wayne Kuznar
October 2014, Vol 5 , No 8
Los Angeles, CA—Oncology practices are evolving in an era of cost containment and a renewed focus on quality. At the Fourth Annual Conference of the Association for Value-Based Cancer Care, John D. Sprandio, MD, Chief of Medical Oncology and Hematology at Oncology Management Services, Ltd.
Read More
New Mexico Oncology Medical Home
Cancer Center Profile
October 2014, Vol 5 , No 8
Value-Based Cancer Care
(VBCC) discussed these questions with Barbara L. McAneny, MD, CEO, New Mexico Oncology Hematology Consultants, who established the New Mexico Cancer Center’s Oncology Medical Home as part of the COME HOME award from the Center for Medicare and Medicaid Innovation.
Read More
Enzalutamide Long-Term Safety and Efficacy in Hormone-Naïve Prostate Cancer
ESMO 2014 - Prostate Cancer
,
ESMO
Conference Correspondent
Read More
Maximal Androgen Depletion with Abiraterone Acetate Followed by Molecular-Targeted Therapies in Metastatic Prostate Cancer: Finding an Androgen-Signaling Signature to Predict Response
ESMO 2014 - Prostate Cancer
,
ESMO
Conference Correspondent
Read More
Chemohormonal Therapy versus Hormonal Therapy Alone in Men with Metastatic Prostate Cancer
ESMO 2014 - Prostate Cancer
,
ESMO
Conference Correspondent
Read More
AR-V7 Splice Variant as Prognostic Marker for Resistance to Enzalutamide or Abiraterone in Men with Metastatic Prostate Cancer
ESMO 2014 - Prostate Cancer
,
ESMO
Conference Correspondent
Read More
Nivolumab versus Investigator’s Choice of Chemotherapy in Patients with Advanced Melanoma
ESMO 2014 - Immuno-Oncology
,
ESMO
Conference Correspondent
Read More
Nivolumab Improves Survival in Ipilimumab-Naïve Patients with Advanced Melanoma
ESMO 2014 - Immuno-Oncology
,
ESMO
Conference Correspondent
Read More
Two Dosing Schedules of Pembrolizumab for Patients with Advanced Melanoma
ESMO 2014 - Immuno-Oncology
,
ESMO
Conference Correspondent
Read More
Updated OS Data for the CA184-043 Trial: Immunotherapy with Ipilimumab Does Not Improve Survival in Patients with Metastatic Prostate Cancer
ESMO 2014 - Immuno-Oncology
,
ESMO
Conference Correspondent
Read More
Page 214 of 330
211
212
213
214
215
216
217
Top Trending Articles
1.
FDA Approves Acalabrutinib and Venetoclax Combination for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2.
FDA Launches Unified Adverse Event Monitoring System to Enhance Transparency and Efficiency
3.
Financial Toxicity in Cancer Care: Why the Conversation Must Start Before Treatment Begins
Jan Hailey, MHL, CMC, CMCO, CMIS, CMOM, CMCA-E/M
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma